Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 23, Issue 8, Pages 1009-1020
Publisher
Elsevier BV
Online
2022-07-08
DOI
10.1016/s1470-2045(22)00369-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures
- (2021) Kathryn M. Appleton et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma
- (2021) Talia Golan et al. GASTROENTEROLOGY
- Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2
- (2021) Kim A. Reiss et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial
- (2021) Laetitia Dahan et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
- (2021) G. Orsi et al. ESMO Open
- A Phase 2 Study of Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
- (2020) Annie A. Wu et al. CLINICAL CANCER RESEARCH
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
- (2019) Andrea Wang-Gillam et al. EUROPEAN JOURNAL OF CANCER
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- Mitotic progression following DNA damage enables pattern recognition within micronuclei
- (2017) Shane M. Harding et al. NATURE
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
- (2015) T. Higuchi et al. Cancer Immunology Research
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
- (2014) T Golan et al. BRITISH JOURNAL OF CANCER
- Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial
- (2013) Michele Reni et al. EUROPEAN JOURNAL OF CANCER
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now